FDA: Cosmetic Warning Letters Carry Same Weight Regardless Of Issuing Office

Around 96% of warning letters for excessive cosmetics claims in 2016 have issued from FDA district offices as opposed to CFSAN headquarters, representing a marked shift from previous years. The agency stresses, however, that the source of a warning letter has no bearing on its implications.

Warning Rubber Stamp

An FDA warning letter for unapproved drug claims on cosmetic products is far more likely to come from one of the agency’s district offices in 2016 versus years past, but recipients should treat such warnings with no less gravity than those that issue from the Center for Food Safety and Applied Nutrition’s headquarters.

In an Oct. 3 email, Marianna Naum, who handles strategic communications and public engagement within FDA’s Office of Foods and...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from United States

Different Name, Same Contamination, Recall Problems For US Homeopathic Nasal Spray Firm

Green Pharmaceuticals’ SnoreStop Nasal Spray, previously marketed as “NasoSpray,” still is available even though agency officials on multiple occasions for a month recommended a recall after an April inspection found “gross microbial contamination” in one lot.

Lauder’s Outgoing CFO Breaks Down Global Prestige Beauty, Firm’s Transition Moment

 

Global beauty giant is working to adapt its approach to the prestige market to meet escalating competition, increased points of sale, and more knowledgeable consumers with new shopping habits, CFO Tracey Travis said at the Barclays Global Consumer Staples Conference.

Perrigo Securities Class-Action Settlement Awards Attorneys’ Fees, Expenses Lower Than Requested

 

Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.

More from North America

US FDA Adcomm Reform Ideas: Neutral Facilitator As Chair, Public Hearing Lottery Process Tweaks

 
• By 

Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process. 

Kratom Industry Argues FDA Wants To Label All Products As Adverse Events Without Evidence

 

Week after publishing safety alert about OPMS Black Liquid Kratom “linked to serious adverse health effects, including death,” FDA announced market research “to understand and characterize emergent risk/safety and perceived benefits reportedly linked to kratom and psychedelics.” But it withdrew the study 10 days later.

ACNU Switch And IND Exemption Final Rules Targeted For October In FDA Regulatory Goals

 

Semi-annual regulatory agenda of non-binding target dates also sets December goal for an NPRM to recognize N-acetyl-L-cysteine as a lawful dietary ingredient. Like IND exemptions rule, item on NAC included for first time in FDA’s list.